The Arab Drug Company (EGX:ADCI)

Market Cap	3.25B +20.7%
Revenue (ttm)	1.37B +22.5%
Net Income	232.38M +16.2%
EPS	19.37 +13.4%
Shares Out	12.00M
PE Ratio	13.98
Forward PE	n/a
Dividend	5.00 (1.85%)
Ex-Dividend Date	Nov 25, 2026

Volume	6,463
Open	273.31
Previous Close	273.31
Day's Range	270.00 - 274.98
52-Week Range	140.00 - 389.99
Beta	0.48
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 19, 2026

About The Arab Drug Company

The Arab Drug Company engages in the manufacture and sale of pharmaceutical products. The company offers anti parkinsonism, dermatological, cardiovascular, anti-hypertensive, anti-platelets, analgesic, anti-pyretic, anti-inflammatory, antimigraine, topical anti-fungal, respiratory tract, gynecological, anemia and optic atrophy, oral corticosteroid, anesthetics, topical antiviral, antibacterial and anti-infective, anti-acne, nasal decongestants, anti-diarrheal, antihistamines, mucolytics, antiemetic, allergic rhinitis, anti-vertigo, gingivitis, ...

• Industry: Pharmaceutical Preparations
• Founded: 1963
• Employees: 1,148
• Stock Exchange: Egyptian Stock Exchange
• Ticker Symbol: ADCI

Financial Performance

In fiscal year 2026, The Arab Drug Company's revenue was 1.37 billion, an increase of 22.54% compared to the previous year's 1.12 billion. Earnings were 232.38 million, an increase of 13.43%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 14, 2026

Data Sources Report a data error